MUC20

Across TCGA pan-cancer cohorts, MUC20 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MUC20 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MUC20 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MUC20 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where MUC20 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	1.000	0.132	.006	29	view →
LSCC	OS	Quartile	All	0.559	0.928	.019	8	view →
CCRCC	DFS	Median	II,III,IV	0.839	1.000	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MUC20–LUAD (DFS)

Open the LUAD breakdown →